32 Infos zu Kajo Kallen

8 Aktuelle Nachrichten

CureVac GmbH /CureVac presents convincing data from the first ever Phase I/IIa clinical study with a mRNA based vaccine Processed and transmitted ...

Investegate announcements from CureVac GmbH, CureVac presents convincing data from the first...

CureVac GmbH / CureVac präsentiert überzeugende Daten zu der weltweit ersten klinischen Phase-I/IIa-Studie mit einer mRNA-Vakzine Verarbeitet und übermittelt...

... hinaus konnte eine Reaktion auf alle Antigene beobachtet werden. Diese Daten sind äußerst ermutigend", sagte Dr. Kajo Kallen, CSO von CureVac.

2 Profile in Sozialen Netzwerken

Life Sciences Business Intelligence Web Portal for North America, Europe and Israel

Life Sciences Business Intelligence Web Portal for Germany, Austria and Switzerland

1 Hobbys & Interessen

Curevac Gmbh Hugin-News: CureVac GmbH

1 Bücher zum Namen

Authoritative and cutting-edge, RNA Vaccines: Methods and Protocols aims to increased collaboration on RNA vaccines between basic and applied scientists in academia, government, and industry to develop future solutions for today's challenges Thomas Hinz, Kajo Kallen, Cedrik M. Britten, Bruno Flamion, Ulrich Granzer, Axel Hoos, Christoph ...

1 Allgemeine Veröffentlichungen

A variety of different mRNA-based drugs are currently in development. This became possible, since major breakthroughs in RNA research during the last decades...

19 Webfunde aus dem Netz

In Zusammenhang mit CureVac GmbH,

... Germany) Thomas Hinz (PEI, Langen, Germany) Kajo Kallen (Curevac, Tübingen, Germany) Sebastian Kreiter (TRON, Mainz, Germany) Michael Wolf (Merck ...

The data once again demonstrates the great potential of RNActive® vaccination technology," says Dr. Kajo Kallen, CSO/CMO of CureVac. Both trials show that RNActive® vaccines have a very good safety profile and trigger strong, balanced antigen-specific immune responses from both human T- …

CureVac AG, High immune response rate of 84% in heavily pre-treated NSCLC patients - First evidence for induction of pre-germ…

... sehr ermutigend. Sie bestätigen unsere bisherigen Ergebnisse aus Studien an Patienten mit Prostatakrebs“, sagt Dr. Kajo Kallen,

... Mainz, Germany) Ugur Sahin (TRON, Mainz, Germany) Christoph Huber (CIMT, Mainz, Germany) Thomas Hinz (PEI, Langen, Germany) Kajo Kallen (CureVac ...

central resource for events in human genetics and molecular biology

CureVac GmbH Presents Convincing Data from the First Ever Phase I/IIa Clinical Study With a mRNA Based Vaccine - read this article along with other careers...

Potential der RNActive® Vakzinierungstechnologie“, sagte PD Dr. Dr. Kajo Kallen, CSO/CMO der. CureVac. Beide Studien deuten darauf hin, ...

Dokter Karl-Josef 'Kajo' Kallen is vanaf heden Chief Medical Officer van het bedrijf.

... Reyn CSO: Kris Thielemans CMO: Kajo Kallen More information: Groot-Begijnhof B Leuven, Belgium - Telephone +32-(0)16/ Telefax +32-(0)16/.

Kajo Kallen, Cure Vac, Tubingen,. mRNA-based vaccines: immunogenicity results from phase I/IIa studies in prostate carcinoma.

A variety of different mRNA-based drugs are currently in development. This became possible, since major breakthroughs in RNA research during the last decades...

Thomas Hinz, Kajo Kallen, Cedrik M. Britten, Bruno Flamion, Ulrich Granzer, Axel Hoos, Christoph Huber, Samir Khleif, Sebastian Kreiter, Hans Georg ...

:20-16:40 Karl-Josef Kajo KALLEN Messenger RNA-based vaccines: a new approach to immunization 16:40-17:00 Afternoon break CONCLUDING PANEL ...

Thomas Hinz, Kajo Kallen, Cedrik M. Britten, Bruno Flamion, Ulrich Granzer, Axel Hoos, Christoph Huber, Samir Khleif, Sebastian Kreiter, Hans Georg ...

PMV, LSP, Omega Funds. • Boehringer Ingelheim VF. Management team. • CEO: Dirk Reyn. • CSO: Kris Thielemans. • CMO: Kajo Kallen. More information: ...

fund+ announces eur 125 million closing of life sciences